Marcello Gambacorta

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Andrea Lombardi Borgia, Antonella Isacchi, Roberta Bosotti, 2014, Molecular oncology.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Enzo Medico, Roberta Schiavo, F. Nicolantonio, 2012, Nature.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Davide Corà, Claudio Isella, Enzo Medico, 2011, Cancer discovery.

Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis.

Maurizio Vertemati, Mara Cossa, M. Gambacorta, 2012, Pathology, research and practice.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Andrea Bertotti, Simona Corso, Maria Apicella, 2013, Cancer discovery.

Quantitative Analysis of Mycobacterial and Propionibacterial DNA in Lymph Nodes of Japanese and European Patients with Sarcoidosis

Shoji Kudoh, Andrew G. Nicholson, A. Nicholson, 2002, Journal of Clinical Microbiology.

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

Silvia Benvenuti, M. Moroni, A. Bardelli, 2005, The Lancet. Oncology.